case_images: PMC10876828_01
case_images: PET-CT on 4 November 2020.
case_images: fonc-14-1297156-g001.jpg
case_images: PMC10876828_01_fonc-14-1297156-g001.jpg
case_images: f1
case_images: The positron emission tomography (PET) scan on 4 November 2020 showed a hypermetabolic nodule in the left upper lobe with obstructive inflammation, which was considered as pulmonary malignancy first; small lymph nodes in the left upper hilum and mediastinal region 5 suggested the possibility of metastasis ( Figure 1 ).
case_images: Treatment timeline and clinical response. (A) Diagram illustrating the different therapies, including precise timing and therapeutic evaluation. (B) CT imaging after surgery. (C) CT imaging after 2 months of Osimertinib treatment. (D) CT imaging after 4 months of Osimertinib treatment. (E) CT imaging after 1 month of Afatinib treatment. (F) CT imaging after two courses of combination therapy of pemetrexed and carboplatin. (G) CT imaging after two courses of combination therapy of docetaxel and carboplatin. (H) CT imaging after 1 month of T+S therapy. (I) CT imaging after 3 months of T+S therapy. (J) CT imaging after 5 months of T+S therapy.
case_images: fonc-14-1297156-g002.jpg
case_images: PMC10876828_01_fonc-14-1297156-g002.jpg
case_images: f2
case_images: Magnetic resonance imaging (MRI) of the brain showed no metastasis.  Figure 2  displays his treatment history and the chest computed tomography (CT) images.
case_images: PMC10876828_02
case_images: PET-CT on 10 April 2022.
case_images: fonc-14-1297156-g003.jpg
case_images: PMC10876828_02_fonc-14-1297156-g003.jpg
case_images: f3
case_images: The PET/CT scan is shown in  Figure 3 .
case_images: Chest CT imaging of the patient at various time points of the patient's treatment.
case_images: fonc-14-1297156-g004.jpg
case_images: PMC10876828_02_fonc-14-1297156-g004.jpg
case_images: f4
case_images: CT after 2 weeks showed a reduction in the left lung lesion. The patient remained stable with a progression-free survival (PFS) of 5 months until PD on 2 April 2023. Chest CT imaging and the brain MRI of the patient at various time points before and after treatment are shown in  Figures 4 ,  5 .
case_images: Brain MRI of the patient at various time points of the patient's treatment.
case_images: fonc-14-1297156-g005.jpg
case_images: PMC10876828_02_fonc-14-1297156-g005.jpg
case_images: f5
case_images: CT after 2 weeks showed a reduction in the left lung lesion. The patient remained stable with a progression-free survival (PFS) of 5 months until PD on 2 April 2023. Chest CT imaging and the brain MRI of the patient at various time points before and after treatment are shown in  Figures 4 ,  5 .